Thanks, John, and good morning, everyone. Let's take a look at our first quarter financial performance found on slide 12. Terex is in a strong financial position. We demonstrated excellent execution in a dynamic environment. Sales of $1.2 billion were up 23% year-over-year on higher volume and improved price realization necessary to mitigate rising costs. Sales in constant currency were up 27% as foreign currency translation negatively impacted sales by $42 million, or approximately 4% in the quarter as the Euro and British Pound weakened against the dollar. Gross margins increased by 410 basis points in the quarter as volume, pricing, favorable product mix, improved manufacturing efficiencies and strict expense discipline helped to offset costs increases and the negative impact of foreign exchange rates. Both segments recorded a year-over-year increase in gross margin. SG&A was 10.6% of sales and decreased by 50 basis points from the prior-year as business investment and marketing costs were coupled with continued expense management. SG&A increased over the prior-year year due to inflation, unfavorable foreign exchange, incremental spend on new acquisition, and increased marketing expenses, and tradeshows. Income from operations of $148 million was up 98% year-over-year. Operating margin of 12% was up 460 basis points compared to the prior year. Our incremental margin was 31% compared to the last year. Interest and other expense of $15 million increased $4 million from the prior year due to increased interest rates. The first quarter global effective tax rate was 17.5%. First quarter earnings per share of $1.60 more than doubled representing a $0.86 improvement over last year. This strong performance was driven by increased volume, disciplined pricing, and continued cost management. This quarter includes an unfavorable earnings per share impact of $0.10 from foreign exchange translation. Free cash flow for the quarter was negative $11 million, representing a significant improvement over the prior year. I will discuss free cash flow later in more detail. Let's look at our segment results, starting with our Materials Processing segment found on slide 13. MP had yet another excellent quarter with consistently strong operational execution. Sales of $554 million increased 22% compared to the first quarter of 2022 with healthy demand for our product across multiple businesses. On foreign exchange neutral basis, sales were up 28%. Bookings were up 6% sequentially. MP ended the quarter with backlog of $1.2 billion. The backlog remains robust and is approximately three times historical norms. MP delivered operating profit of 15.4%, up 120 basis points over the prior year driven by higher sales volume, favorable product mix, and disciplined cost management, resulting in an incremental margin of 21%. On slide 14, see our aerial work platform segment financial results. AWP had an excellent quarter with sales of $686 million, up 24% compared to the prior year on higher demand. On a foreign exchange neutral basis, sales increased 27%. Backlog at quarter end was $2 billion, up 4% from the prior year. Bookings remained strong with a book-to-bill ratio of 112%. AWP more than doubled their operating profit and delivered operating margins of 12.1% in the quarter, up 620 basis points from last year with an incremental margin of 38%. The improvement was a result of higher sales volume, favorable mix, cost reduction initiatives, manufacturing efficiencies, and disciplined pricing actions to offset martial supplier cost. Please see slide 15 for an overview of our disciplined capital allocation strategy. The company's strong balance sheet provides us the financial flexibility for the future. As a reminder, although Terex does provide customer financing solutions through our banking partners, in February of 2021, we sold our TFS asset. And no longer carry this exposure on our balance sheet. We remain diligent in managing counterparty exposure and risk as well as regional customer and supplier risk. Today, we have not seen a negative impact due to current market conditions. Free cash flow for the quarter was negative $11 million compared to negative $72 million a year ago. This $61 million year-over-year improvement in free cash flow was due to increased operating profit. Hospital inventory at the end of the first quarter was $48 million. An increase of $12 million from the fourth quarter of last year and down slightly from a year ago reflecting continued supply chain disruption. We continue to invest in our business with capital expenditures and investments of $30 million. We increased our quarterly dividend per share to $0.15. A 15% increase over the prior year. We repurchased $3 million of shares in the first quarter. In April, we have continued our share repurchase program, and purchased 14 million of shares partially offsetting the dilution from our compensation programs in March. Through April, we have returned $28 million to shareholders, and have $175 million remaining on our share repurchase program. We will offset dilution, and take advantage of market dislocation in these volatile times. We have no debt maturities until 2026, and 77% of our debt is at a fixed rate of 5% until the end of the decade. Our net leverage remains low at one-time, which is well below our 2.5 times target through the cycle. We had ample liquidity of $677 million. The company is in an excellent position to run and grow the business. Now, turning to slide 16, and our updated full-year outlook, it is important to realize we are operating in a challenging macro environment with many variables and geopolitical uncertainties. So, these all could change negatively or positively. With that said, this updated outlook represents our best estimate as of today. Thanks to the strong execution of our team members and our robust backlog, we are pleased to raise our 2023 outlook. We now expect earnings per share of $5.60 to $6. Our increased sales outlook of $4.8 billion to $5 billion incorporates the latest dialog with our customers and our suppliers. We anticipate higher volume as customer demand remains strong. Our sales are expected to be relatively consistent in Q2 and Q3, and down slightly in Q4, due to lower production days. Our operating margin outlook has increased to a range of 11.4% 11.8%. This reflects our excellent performance in the first quarter, continued strong customer demand, the latest information from our supply chain, cost benefits, and continued strict expense management. We expect to improve free cash flow in the next three quarters, and we are raising our outlook to $300 million to $350 million, primarily due to higher earnings. Let's take a look at our updated segment outlook. Based upon MP's continued strong execution, which include continued mitigation of cost pressures and supply chain challenges, we are increasing our sales outlook to range of $2.1 billion to $2.2 billion, with an increased operating margin of approximately 15.8%. We expect MP sales and margins to be relatively consistent for the remainder of the year. The AWP team has increased their factory output. And as a result, we are increasing our sales outlook to range of $2.7 billion to $2.8 billion. Incorporating the increased volumes, the team's cost reduction activities, pricing actions, and improved manufacturing efficiencies, we are raising our full-year operating margin outlook to approximately 11.5%. We anticipate AWP sales to be relatively consistent in Q2 and Q3, and down slightly in Q4 due to normal seasonality and lower production days. AWP margins are expected to be negatively impacted by manufacturing inefficiencies due to scheduled production moves to our Monterrey facility, which will have a greater impact in the second-half of the year. And with that, I will turn it back to you, John.